Actinium Pharmaceuticals

Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.
New York, US
18 (est)+50%

Actinium Pharmaceuticals Locations

New York, US

Actinium Pharmaceuticals Metrics

Actinium Pharmaceuticals Summary

Founding Date


Market capitalization

$52.5 M

Closing share price


Actinium Pharmaceuticals Market Value History

Actinium Pharmaceuticals News

Actinium Pharmaceuticals Company Life